Correlation between oculometric measures and clinical assessment in ALS patients participating in a phase IIb clinical drug trial

References

• Anderson TJ, MacAskill MR. Eye movements in patients with neurodegenerative disorders. Nat Rev Neurol. 2013;9:74–85.
   PubMed Web of Science ®Google Scholar
• Mahanama B, Jayawardana Y, Rengarajan S, Jayawardena G, Chukoskie L, Snider J, et al. Eye movement and pupil measures: a review. Front Comput Sci. 2022;3:733531.
   Web of Science ®Google Scholar
• Proudfoot M, Menke RA, Sharma R, Berna CM, Hicks SL, Kennard C, et al. Eye-tracking in amyotrophic lateral sclerosis: a longitudinal study of saccadic and cognitive tasks. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:101–11.
   PubMed Web of Science ®Google Scholar
• Beaufils E, Corcia P, de Toffol B, Praline J. Occurrence of eye movement disorders in motor neuron disease. Amyotroph Lateral Scler. 2012;13:84–6.
   PubMed Web of Science ®Google Scholar
• Donaghy C, Thurtell MJ, Pioro EP, Gibson JM, Leigh RJ. Eye movements in amyotrophic lateral sclerosis and its mimics: a review with illustrative cases. J Neurol Neurosurg Psychiatry. 2011;82:110–6.
   PubMed Web of Science ®Google Scholar
• Sharma R, Hicks S, Berna CM, Kennard C, Talbot K, Turner MR. Oculomotor dysfunction in amyotrophic lateral sclerosis: a comprehensive review. Arch Neurol. 2011;68:857–61.
   PubMed Web of Science ®Google Scholar
• Donaghy C, Pinnock R, Abrahams S, Cardwell C, Hardiman O, Patterson V, et al. Slow saccades in bulbar-onset motor neurone disease. J Neurol. 2010;257:1134–40.
   PubMed Web of Science ®Google Scholar
• Rekik A, Mrabet S, Kacem I, Nasri A, Ben Djebara M, Gargouri A, et al. Eye movement abnormalities in amyotrophic lateral sclerosis in a Tunisian cohort. Neuroophthalmology. 2022;46:227–35.
   PubMed Web of Science ®Google Scholar
• Takeda T, Uchihara T, Mochizuki Y, Ishihara A, Nakamura A, Sasaki S, et al. Supranuclear ophthalmoparesis and vacuolar degeneration of the cerebral white matter in amyotrophic lateral sclerosis: a clinicopathological study. Amyotroph Lateral Scler. 2012;13:74–83.
   PubMed Web of Science ®Google Scholar
• Takeda T, Kitagawa K, Arai K. Phenotypic variability and its pathological basis in amyotrophic lateral sclerosis. Neuropathology. 2020;40:40–56.
   PubMed Web of Science ®Google Scholar
• Rojas P, Ramírez AI, Fernández-Albarral JA, López-Cuenca I, Salobrar-García E, Cadena M, et al. Amyotrophic lateral sclerosis: a neurodegenerative motor neuron disease with ocular involvement. Front Neurosci. 2020;14:566858.
   PubMed Web of Science ®Google Scholar
• Guo X, Liu X, Ye S, Liu X, Yang X, Fan D. Eye movement abnormalities in amyotrophic lateral sclerosis. Brain Sci. 2022;12:489.
   PubMed Web of Science ®Google Scholar
• Coe BC, Munoz DP. Mechanisms of saccade suppression revealed in the anti-saccade task. Philos Trans Royal Soc B Biol Sci. 2017;372:20160192.
   PubMed Web of Science ®Google Scholar
• Ellmerer P, Peball M, Carbone F, Ritter M, Heim B, Marini K, et al. Eye tracking in patients with Parkinson’s disease treated with nabilone–results of a phase II, placebo-controlled, double-blind, parallel-group pilot study. Brain Sci. 2022;12:661.
   PubMed Web of Science ®Google Scholar
• Yae Y, Yuge K, Maeda T, Ichinose F, Matsuo M, Kobayashi O, et al. Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen. Front Neurol. 2022;13. DOI: 10.3389/fneur.2022.918255
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. Bdnf Als Study Group, 1A complete listing of the BDNF Study Group. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Gorges M, Müller HP, Lulé D, Del Tredici K, Brettschneider J, Keller J, et al. Eye movement deficits are consistent with a staging model of pTDP-43 pathology in amyotrophic lateral sclerosis. PLOS One. 2015;10:e0142546.
   PubMed Web of Science ®Google Scholar
• Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414–25.
   PubMed Web of Science ®Google Scholar
• Barp A, Gerardi F, Lizio A, Sansone VA, Lunetta C. Emerging drugs for the treatment of amyotrophic lateral sclerosis: a focus on recent phase 2 trials. Expert Opin Emerg Drugs. 2020;25:145–64.
   PubMed Web of Science ®Google Scholar
• Nefussy B, Drory VE. Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: novel developments and future directions in diagnosis, genetics, pathogenesis and therapies. EPMA J. 2010;1:329–41.
   PubMedGoogle Scholar
• Gordon PH, Miller RG, Moore DH. ALSFRS ‐R Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:90–3.
   Google Scholar
• Kang BH, Kim JI, Lim YM, Kim KK. Abnormal oculomotor functions in amyotrophic lateral sclerosis. J Clin Neurol. 2018;14:464–71.
   PubMed Web of Science ®Google Scholar
• Zaino D, Serchi V, Giannini F, Pucci B, Veneri G, Pretegiani E, et al. Different saccadic profile in bulbar versus spinal-onset amyotrophic lateral sclerosis. Brain. 2023;146:266–77.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Bedlack R, Andrews JA, Berry JD, Bowser R, Brown R, et al. Amyotrophic lateral sclerosis clinical trials and interpretation of functional end points and fluid biomarkers: a review. JAMA Neurol. 2022;79:1312–8.
   PubMed Web of Science ®Google Scholar
• Staats KA, Borchelt DR, Tansey MG, Wymer J. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol Neurodegener. 2022;17:11.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties? J Clin Epidemiol. 1992;45:1341–5.
   PubMed Web of Science ®Google Scholar